Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials .
There was an increased risk of short-term AEs with cannabinoids , including serious AEs .
Common AEs included dizziness , dry mouth , nausea , fatigue , somnolence , euphoria , vomiting , disorientation , drowsiness , confusion , loss of balance , and hallucination .
CONCLUSIONS AND RELEVANCE There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity .
There was low- quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy , weight gain in HIV infection , sleep disorders , and Tourette syndrome .
Cannabinoids were associated with an increased risk of short-term AEs
IMPORTANCE Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms , but their efficacy for specific indications is not clear .
OBJECTIVE To conduct a systematic review of the benefits and adverse events ( AEs ) of cannabinoids .
Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting.
AIMS Despite progress in anti-emetic treatment , many patients still suffer from chemotherapy-induced nausea and vomiting ( CINV ) . This is a pilot , r and omized , double-blind , placebo-controlled phase II clinical trial design ed to evaluate the tolerability , preliminary efficacy , and pharmacokinetics of an acute dose titration of a whole-plant cannabis-based medicine ( CBM ) containing delta-9-tetrahydrocannabinol and cannabidiol , taken in conjunction with st and ard therapies in the control of CINV . METHODS Patients suffering from CINV despite prophylaxis with st and ard anti-emetic treatment were r and omized to CBM or placebo , during the 120 h  post-chemotherapy  period , added to st and ard anti-emetic treatment .  Tolerability was measured as the number of withdrawals from the study during the titration period because of adverse events ( AEs ) . The endpoint for the preliminary efficacy analysis was the proportion of patients showing complete or partial response . RESULTS Seven patients were r and omized to CBM and nine to placebo . Only one patient in the CBM arm was withdrawn due to AEs . A higher proportion of patients in the CBM group experienced a complete response during the overall observation period [ 5/7 ( 71.4 % ) with CMB vs. 2/9 ( 22.2 % ) with placebo , the difference being 49.2 % ( 95 % CI 1 % , 75 % ) ] , due to the delayed period . The incidence of AEs was higher in the CBM group ( 86 % vs. 67 % ) . No serious AEs were reported . The mean daily dose was 4.8 sprays in both groups . CONCLUSION Compared with placebo , CBM added to st and ard antiemetic therapy was well tolerated and provided better protection against delayed CINV . These results should be confirmed in a phase III clinical trial
Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials .
There was an increased risk of short-term AEs with cannabinoids , including serious AEs .
Common AEs included dizziness , dry mouth , nausea , fatigue , somnolence , euphoria , vomiting , disorientation , drowsiness , confusion , loss of balance , and hallucination .
CONCLUSIONS AND RELEVANCE There was moderate- quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity .
There was low- quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy , weight gain in HIV infection , sleep disorders , and Tourette syndrome .
Cannabinoids were associated with an increased risk of short-term AEs
IMPORTANCE Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms , but their efficacy for specific indications is not clear .
OBJECTIVE To conduct a systematic review of the benefits and adverse events ( AEs ) of cannabinoids .